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Objectives: To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged
65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.
Trial design: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial.
Participants will be randomly allocated 1:1:1:1:1 to the following strategies:
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 Arm 1: Control arm
 Arms 2 to 5: Experimental treatment arms
Planned interim analyses will be conducted at regular intervals. Their results will be reviewed by an Independent Data
and Safety Monitoring Board. Experimental arms may be terminated for futility, efficacy or toxicity before the end of
the trial. New experimental arms may be added if new evidence suggests that other treatments should be tested.
A feasibility and acceptability substudy as well as an immunological substudy will be conducted alongside the trial.
Participants: Inclusion criteria are: 65-year-old or more; Positive test for SARS-CoV-2 on a nasopharyngeal swab;
Symptoms onset within 3 days before diagnosis; No hospitalisation criteria; Signed informed consent; Health insurance.
Exclusion criteria are: Inability to make an informed decision to participate (e.g.: dementia, guardianship); Rockwood
Clinical Frailty Scale ≥7; Long QT syndrome; QTc interval > 500 ms; Heart rate <50/min; Kalaemia >5.5 mmol/L or <3.5
mmol/L; Ongoing treatment with piperaquine, halofantrine, dasatinib, nilotinib, hydroxyzine, domperidone, citalopram,
escitalopram, potent inhibitors or inducers of cytochrome P450 CYP3A4 isoenzyme, repaglinide, azathioprine, 6-
mercaptopurine, theophylline, pyrazinamide, warfarin; Known hypersensitivity to any of the trial drugs or to chloroquine
and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB; Hepatic porphyria; Liver
failure (Child-Pugh stage ≥B); Stage 4 or 5 chronic kidney disease (GFR <30 mL/min/1.73 m²); Dialysis; Hypersentivity to
lactose; Lactase deficiency; Abnormalities in galactose metabolism; Malabsorption syndrome; Glucose-6-phosphate
dehydrogenase deficiency; Symptomatic hyperuricemia; Ileus; Colitis; Enterocolitis; Chronic hepatitis B virus disease.
The trial is being conducted in France in the Bordeaux, Corse, Dijon, Nancy, Paris and Toulouse areas as well as in the
Grand Duchy of Luxembourg. Participants are recruited either at home, nursing homes, general practices, primary care
centres or hospital outpatient consultations.
Intervention and comparator: The four experimental treatments planned in protocol version 1.2 (April 8th, 2020) are:
(1) Hydroxychloroquine 200 mg, 2 tablets BID on day 0, 2 tablets QD from day 1 to 9; (2) Imatinib 400 mg, 1 tablet QD
from day 0 to 9; (3) Favipiravir 200 mg, 12 tablets BID on day 0, 6 tablets BID from day 1 to 9; (4) Telmisartan 20 mg, 1
tablet QD from day 0 to 9.
The comparator is a complex of vitamins and trace elements (AZINC Forme et Vitalité®), 1 capsule BID for 10 days, for
which there is no reason to believe that they are active on the virus.
In protocol version 1.2 (April 8th, 2020): People in the control arm will receive a combination of vitamins and trace
elements; people in the experimental arms will receive hydroxychloroquine, or favipiravir, or imatinib, or telmisartan.
Main outcome: The primary outcome is the proportion of participants with an incidence of hospitalisation and/or death
between inclusion and day 14 in each arm.
Randomisation: Participants are randomized in a 1:1:1:1:1 ratio to each arm using a web-based randomisation tool.
Participants not treated with an ARB or ACEI prior to enrolment are randomized to receive the comparator or one of the
four experimental drugs. Participants already treated with an ARB or ACEI are randomized to receive the comparator or
one of the experimental drugs except telmisartan (i.e.: hydroxychloroquine, imatinib, or favipiravir). Randomisation is
stratified on ACEI or ARBs treatment at inclusion and on the type of residence (personal home vs. nursing home).
Blinding (masking): This is an open-label trial. Participants, caregivers, investigators and statisticians are not blinded to
group assignment.
Numbers to be randomised (sample size): A total of 1057 participants will be enrolled if all arms are maintained until
the final analysis and no additional arm is added.
Three successive futility interim analyses are planned, when the number of participants reaches 30, 60 and 102 in the
control arm. Two efficacy analyses (interim n°3 and final) will be performed successively.
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Trial Status: This describes the Version 1.2 (April 8th, 2020) of the COVERAGE protocol that was approved by the French
regulatory authority and ethics committee. The trial was opened for enrolment on April 15th, 2020 in the Nouvelle
Aquitaine region (South-West France). Given the current decline of the COVID-19 pandemic in France and its
unforeseeable dynamic in the coming months, new trial sites in 5 other French regions and in Luxembourg are currently
being opened. A revised version of the protocol was submitted to the regulatory authority and ethics committee on
June 15th, 2020. It contains the following amendments: (i) Inclusion criteria: age ≥65 replaced by age ≥60; time since first
symptoms <3 days replaced by time since first symptoms <5 days; (ii) Withdrawal of the hydroxychloroquine arm (due
to external data); (iii) increase in the number of trial sites.
Trial registration: The trial was registered on Clinical Trials.gov on April 22nd, 2020 (Identifier: NCT04356495): and on
EudraCT on April 10th, 2020 (Identifier: 2020-001435-27).
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In
the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as
a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the
Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04619-1.
Additional file 1. COVERAGE trial protocol version 1.2 (April 8th 2020).
Additional file 2. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
Additional file 3. List of members of the COVERAGE study group.
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